Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0988 USD | +3.95% | 0.00% | -14.09% |
2023 | Earnings Flash (FZMD) FUSE MEDIAL Reports Q2 Revenue $5M | MT |
2023 | Fuse Medical, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 | CI |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|
Capitalization 1 | 36.12 | 21.07 | 13.2 | 30.2 | 10.55 |
Enterprise Value (EV) 1 | 36.9 | 21.87 | 13.79 | 32.42 | 12.75 |
P/E ratio | 8.6 x | -6 x | -9.22 x | -19 x | 3.75 x |
Yield | - | - | - | - | - |
Capitalization / Revenue | 1.37 x | 0.92 x | 0.62 x | 1.48 x | 0.57 x |
EV / Revenue | 1.4 x | 0.95 x | 0.64 x | 1.59 x | 0.68 x |
EV / EBITDA | -19.3 x | -6.61 x | -14.9 x | -15.2 x | -18.8 x |
EV / FCF | 24.4 x | 16.5 x | 9.76 x | -82.1 x | 11.8 x |
FCF Yield | 4.1% | 6.07% | 10.2% | -1.22% | 8.46% |
Price to Book | 23.9 x | -17.2 x | -6.25 x | -8.81 x | -33.9 x |
Nbr of stocks (in thousands) | 72,222 | 70,222 | 70,222 | 70,222 | 70,322 |
Reference price 2 | 0.5001 | 0.3000 | 0.1880 | 0.4300 | 0.1500 |
Announcement Date | 3/21/19 | 3/30/20 | 3/31/21 | 3/31/22 | 4/14/23 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net sales 1 | 26.41 | 26.34 | 22.9 | 21.4 | 20.41 | 18.64 |
EBITDA 1 | 1.027 | -1.909 | -3.311 | -0.9238 | -2.128 | -0.6777 |
EBIT 1 | 1.013 | -1.958 | -3.418 | -1.028 | -2.196 | -0.8151 |
Operating Margin | 3.83% | -7.43% | -14.92% | -4.8% | -10.75% | -4.37% |
Earnings before Tax (EBT) 1 | 0.6997 | 3.571 | -2.535 | -1.414 | -1.57 | 3.122 |
Net income 1 | 0.6997 | 3.958 | -3.316 | -1.432 | -1.588 | 3.098 |
Net margin | 2.65% | 15.02% | -14.48% | -6.69% | -7.78% | 16.62% |
EPS 2 | 0.0400 | 0.0582 | -0.0500 | -0.0204 | -0.0226 | 0.0400 |
Free Cash Flow 1 | 0.195 | 1.512 | 1.327 | 1.412 | -0.395 | 1.079 |
FCF margin | 0.74% | 5.74% | 5.8% | 6.6% | -1.94% | 5.79% |
FCF Conversion (EBITDA) | 18.98% | - | - | - | - | - |
FCF Conversion (Net income) | 27.87% | 38.2% | - | - | - | 34.82% |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 4/6/18 | 3/21/19 | 3/30/20 | 3/31/21 | 3/31/22 | 4/14/23 |
Balance Sheet Analysis
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net Debt 1 | 2.76 | 0.78 | 0.8 | 0.59 | 2.23 | 2.2 |
Net Cash position 1 | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | 2.688 x | -0.4103 x | -0.2426 x | -0.6358 x | -1.048 x | -3.245 x |
Free Cash Flow 1 | 0.19 | 1.51 | 1.33 | 1.41 | -0.4 | 1.08 |
ROE (net income / shareholders' equity) | 53.5% | -121% | -2,712% | 85.9% | 57.3% | -166% |
ROA (Net income/ Total Assets) | 3.26% | -5.91% | -10.5% | -3.59% | -7.68% | -2.68% |
Assets 1 | 21.46 | -66.97 | 31.48 | 39.91 | 20.67 | -115.8 |
Book Value Per Share 2 | -0.1200 | 0.0200 | -0.0200 | -0.0300 | -0.0500 | -0 |
Cash Flow per Share 2 | 0.0100 | 0.0100 | 0.0200 | 0.0200 | 0.0100 | 0 |
Capex 1 | 0.02 | 0.04 | 0.02 | 0.02 | - | - |
Capex / Sales | 0.08% | 0.16% | 0.07% | 0.1% | - | - |
Announcement Date | 4/6/18 | 3/21/19 | 3/30/20 | 3/31/21 | 3/31/22 | 4/14/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-14.09% | 6.94M | |
-2.31% | 187B | |
-3.20% | 106B | |
-5.04% | 66.9B | |
+0.20% | 49.45B | |
+17.29% | 48B | |
+4.06% | 40.84B | |
+2.07% | 26.48B | |
+2.36% | 26.25B | |
+12.96% | 24.62B |
- Stock Market
- Equities
- FZMD Stock
- Financials Fuse Medical, Inc.